N-Methyl-N-isopropylthioacetamid | 59954-26-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代酰胺
• 英文名称: N-Methyl-N-isopropylthioacetamid
• 英文别名: N-methyl-N-propan-2-ylethanethioamide
• CAS: 59954-26-6
• 化学式: C₆H₁₃NS
• 分子量: 131.242
• InChiKey: DUNYPZFFSSTQRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-isopropyl-N-methylacetamide 在 劳森试剂 作用下， 生成 N-Methyl-N-isopropylthioacetamid
  参考文献：
  名称：

  Effect of the orientation of substituents on the chemical shifts of13C. IV—13C NMR spectra ofN,N-diisopropylamides and -thioamides

  摘要：

  AbstractN,N‐diisopropylamides and ‐thioamides show hindered rotation around the NCH bonds, and the presence of mixtures of conformational isomers can be demonstrated at temperatures below 273 K in solution. 1H and 13C NMR spectra of these conformers are measured and assigned. The 13C data serve to study through‐space effects on 13C chemical shifts, which strongly depend on the conformations of the isopropyl groups. For amides, a through‐space shielding of the N‐methine carbons is found to exist only for conformers in which the methine hydrogen atom is spatially close to the oxygen atom. Chemical shift differences between amides and thioamides can be rationalized in terms of through‐bond and through‐space contributions, and serve for a better understanding of the shift differences in N,N‐dialkylamides and ‐thioamides.

  DOI：

  10.1002/mrc.1270160111

文献信息

• [EN] A COLORANT COMPOUND, AND A COLORANT MATERIAL COMPRISING THE SAME<br/>[FR] COMPOSÉ DE COLORANT, ET MATIÈRE DE COLORANT LE COMPRENANT
  申请人：IRIDOS LTD

  公开号：WO2017114742A1

  公开（公告）日：2017-07-06

  A disclosure of the present invention includes novel colorant compounds based on triarylmethane structure, methods for preparing the same, and colorant materials comprising the same.

  本发明的公开包括基于三芳基甲烷结构的新型着色剂化合物、制备该化合物的方法以及包含该化合物的着色材料。
• 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto
  申请人：Teegarden Bradley

  公开号：US20070207994A1

  公开（公告）日：2007-09-06

  The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及某些3-苯基-吡唑衍生物，其具有公式(Ia)和调节5-HT2A血清素受体活性的药物组合物。这些化合物及其药物组合物用于治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、房颤、降低血块形成风险、哮喘或其症状、激动或症状、行为障碍、药物诱导的精神病、兴奋性精神病、抽动秽语综合征、躁狂症、有机或NOS精神病、精神疾病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关障碍，以及睡眠障碍、糖尿病相关障碍、进行性多灶性脑白质病等。本发明还涉及与其他药物一起或分别给药治疗5-HT2A血清素受体介导的疾病的方法。
• Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
  申请人：Teegarden Bradley

  公开号：US20070072857A1

  公开（公告）日：2007-03-29

  The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The present invention also relates to the method of prophylaxis or treatment of 5-HT 2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together.

  本发明涉及公式（I）的某些吡唑衍生物及其制药组合物，可调节5-HT2A 5-羟色胺受体的活性。该化合物及其制药组合物用于预防或治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、心房颤动、减少血栓形成风险、哮喘或其症状、激动或症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de la Tourette综合征、躁狂障碍、有机或NOS精神病、精神障碍、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、睡眠障碍、糖尿病相关疾病等方法。本发明还涉及与多巴胺D2受体拮抗剂（如氟哌啶醇）联合使用的5-HT2A 5-羟色胺受体介导的疾病的预防或治疗方法，可分别或同时给予。
• Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
  申请人：Boatman Douglas P.

  公开号：US20070073062A1

  公开（公告）日：2007-03-29

  The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.

  本发明涉及公式（Ia）的某些融合吡唑衍生物及其药学上可接受的盐，其表现出有用的药理特性，例如作为RUP25受体的激动剂。本发明还提供了包含本发明化合物的药物组合物，以及使用本发明化合物和组合物治疗代谢相关疾病的方法，包括血脂异常、动脉粥样硬化、冠心病、胰岛素抵抗、2型糖尿病、X综合症等。此外，本发明还提供了将本发明化合物与其他活性剂（例如属于α-葡萄糖苷酶抑制剂、醛糖还原酶抑制剂、双胍类、HMG-CoA还原酶抑制剂、角鲨烷合成抑制剂、菸酸类、LDL降解增强剂、血管紧张素转化酶（ACE）抑制剂、胰岛素分泌增强剂、DP受体拮抗剂等）组合使用的方法。
• Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
  申请人：Jones M. Robert

  公开号：US20070072844A1

  公开（公告）日：2007-03-29

  The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.

  本发明涉及公式（I）的某些融合芳基和杂环芳基衍生物，它们是代谢调节剂。因此，本发明的化合物在预防或治疗代谢性疾病及其并发症，如糖尿病和肥胖症方面是有用的。